Pilocytic Astrocytoma (Juvenile Pilocytic Astrocytoma)

Status: draft · Last updated 2026-11-11 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • The basics:
    • WHO grade 1, circumscribed, the most common childhood CNS tumor.
    • About 60% are cerebellar .
  • Imaging: a cyst with an enhancing mural nodule. The nodule is the tumor; an enhancing cyst wall isn't necessarily tumor, and removing it didn't change outcome .
  • Genetics:
    • KIAA1549–BRAF fusion in 66% .
    • Every tumor has a MAPK alteration (BRAF, FGFR1, NTRK2, NF1) .
  • Surgery:
    • Gross total resection is the key :
    • Recurrence about 6–7% after total resection, vs. about 27–52% with residual.
    • Many residuals regress spontaneously.
    • Image for 8–10 years .
  • Medical therapy:
    • Unresectable or progressive tumors: chemotherapy (CV or TPCV; 5-year EFS about 40–50%) .
    • BRAF V600: dabrafenib + trametinib beat chemotherapy .
    • BRAF fusion or NF1: MEK or RAF inhibitors are active .
  • Survival is excellent: OS over 95% at 8 years. Progression and morbidity, not death, are the main problems .

Landmark papers

  • COG natural-history study (Wisoff et al., Neurosurgery 2011): 518 low-grade gliomas managed by surgery then observation. 5- and 8-year OS were 97% and 96% and PFS 80% and 78%, and gross total resection was the dominant predictor of PFS .
  • Dabrafenib plus trametinib (Bouffet et al., N Engl J Med 2023): a randomized phase 2 trial (110 patients) vs carboplatin plus vincristine. Response was 47% vs 11% and median PFS 20.1 vs 7.4 months .

Pilocytic astrocytoma, formerly juvenile pilocytic astrocytoma, is a WHO grade 1, well-circumscribed, often cystic, slow-growing tumor . It is the most common CNS tumor of children and adolescents aged 5–19 . Pilocytic astrocytoma is essentially a single-pathway (MAPK) disease . Where it can be completely removed, surgery is curative. Unresectable midline tumors behave as a chronic disease, managed with chemotherapy and, increasingly, targeted MAPK inhibitors .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:pilocytic:e1e4b15058100518© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Coronal posterior fossa section of a cerebellar pilocytic astrocytoma: a large smooth-walled cyst with an enhancing mural nodule compressing the fourth ventricle, with dilated temporal horns; and a sagittal map of the common sites, cerebellum, optic pathway and hypothalamus, brainstem and cerebral hemispheresCEREBELLAR PILOCYTIC ASTROCYTOMA (CORONAL, POSTERIOR FOSSA)dilated ventricular atria(obstructive hydrocephalus)cyst (non-enhancing wallin the classic pattern)enhancing mural nodule(the tumor)compressed fourthventriclecerebellar hemisphereresection of the nodule is the goalRLCOMMON SITES (MIDSAGITTAL, ANTERIOR LEFT)cerebral hemispheresoptic pathway / hypothalamus(often NF1-associated)brainstem(dorsally exophytic)cerebellum(most common)not to scale
Pilocytic astrocytoma. Top: coronal section of the posterior fossa (patient's right on the viewer's left) showing the classic cerebellar pattern of a large cyst with a non-enhancing wall and an enhancing mural nodule, which is the tumor. The mass compresses the fourth ventricle and causes obstructive hydrocephalus. The surgical goal is resection of the nodule. Bottom: common sites on a midsagittal view: cerebellum (most common), optic pathway and hypothalamus (often NF1-associated), brainstem (often dorsally exophytic) and cerebral hemispheres. Not to scale.

Classification and genetics

Presentation and imaging

Surgery and outcome

Adjuvant and medical therapy (unresectable or progressive tumors)

Related topics

References

  1. Raz E, Zagzag D, Saba L, et al. Cyst with a mural nodule tumor of the brain. Cancer Imaging 2012;12(1):237–244. doi:10.1102/1470-7330.2012.0028. PMID 22935908. verified
  2. Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20(7):1011–1022. doi:10.1016/S1470-2045(19)30277-330277-3). PMID 31151904. verified
  3. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68(21):8673–8677. doi:10.1158/0008-5472.CAN-08-2097. PMID 18974108. verified
  4. Jones DT, Hutter B, Jäger N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013;45(8):927–932. doi:10.1038/ng.2682. PMID 23817572. verified
  5. Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 2023;389(12):1108–1120. doi:10.1056/NEJMoa2303815. PMID 37733309. verified
  6. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
  7. Wisoff JH, Sanford RA, Heier LA, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery 2011;68(6):1548–1554. doi:10.1227/NEU.0b013e318214a66e. PMID 21368693. verified
  8. Ogiwara H, Bowman RM, Tomita T. Long-term follow-up of pediatric benign cerebellar astrocytomas. Neurosurgery 2012;70(1):40–48. doi:10.1227/NEU.0b013e31822ff0ed. PMID 21808215. verified
  9. Due-Tønnessen BJ, Helseth E, Scheie D, et al. Long-term outcome after resection of benign cerebellar astrocytomas in children and young adults (0–19 years): report of 110 consecutive cases. Pediatr Neurosurg 2002;37(2):71–80. doi:10.1159/000065108. PMID 12145515. verified
  10. Kameda-Smith MM, Green K, Hutton DL, et al. The role of reoperation in pediatric cerebellar pilocytic astrocytoma. J Neurosurg Pediatr 2024;34(2):169–175. doi:10.3171/2024.2.PEDS23236. PMID 38759245. verified
  11. Kestle J, Townsend JJ, Brockmeyer DL, et al. Juvenile pilocytic astrocytoma of the brainstem in children. J Neurosurg 2004;101(1 Suppl):1–6. doi:10.3171/ped.2004.101.2.0001. PMID 16206964. verified
  12. Mazloom A, Hodges JC, Teh BS, et al. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int J Radiat Oncol Biol Phys 2012;84(2):350–354. doi:10.1016/j.ijrobp.2011.12.044. PMID 22401918. verified
  13. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol 2012;30(21):2641–2647. doi:10.1200/JCO.2011.36.6054. PMID 22665535. verified
  14. Kilburn LB, Khuong-Quang DA, Hansford JR, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 2024;30(1):207–217. doi:10.1038/s41591-023-02668-y. PMID 37978284. verified

Verification (2026-11-11): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts. The imaging details (60% cerebellar, cyst signal, cyst-wall enhancement, outcome after cyst-wall removal) come from the open-access full text of reference 1 (PMC3458787). The WHO 2021 category and genes come from the full text of reference 6 (PMC8328013), read via a fetch agent.

Caveats: